Mirum Q2 net product sales $77.8M (+139% YoY); LIVMARLI sales $47.2M; positive volixibat interim data

Mirum Pharmaceuticals, Inc.

2024-Q2 EPS reported -$1.06 revenue$147,097,000

Q2 2024 global net product sales $77.8M, up 139% vs Q2 2023; full-year guidance reaffirmed at $310-320M.
LIVMARLI net sales $47.2M (+45% YoY); combined CHOLBAM/CHENODAL sales $30.5M.
Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies.
LIVMARLI approved in Europe for PFIC (≥3 months) and US label expanded to ≥12 months; NDA filed for chenodiol in CTX.
Cash & investments $295.4M (Dec 2023: $286.3M); operating expenses $102.1M vs $61.8M YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.